Rockwell Medical (RMTI) Asset Writedowns and Impairment (2018 - 2026)
Rockwell Medical's (RMTI) quarterly Asset Writedowns and Impairment came in at $68000.0 in Q4 2025, down 84.0% YoY from $425000.0 in Q4 2024, and down 61.8% on a QoQ basis from $178000.0 in Q1 2025.
Rockwell Medical (RMTI) Asset Writedowns and Impairment (2018 - 2026) Analysis & Trends
Rockwell Medical (RMTI) has 8 years of Asset Writedowns and Impairment data on file, last reported at $68000.0 in Q4 2025.
- Quarterly Asset Writedowns and Impairment fell 84.0% year-over-year to $68000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $68000.0 (down 88.72% YoY) and the FY2025 annual result came in at $246000.0, down 42.12% from the prior year.
- Asset Writedowns and Impairment retreated to $68000.0 in Q4 2025, from $178000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.1 million in Q3 2023 to a low of $10000.0 in Q2 2022.
- A 5-year average of $252500.0 and a median of $124500.0 in 2021 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment soared 431.58% — and 2025, when it slumped 84.0%.
- Tracing RMTI's Asset Writedowns and Impairment over 5 years: stood at $57000.0 in 2021, then soared by 431.58% to $303000.0 in 2022, then surged by 262.38% to $1.1 million in 2023, then sank by 61.29% to $425000.0 in 2024, then tumbled by 84.0% to $68000.0 in 2025.
- The last three Asset Writedowns and Impairment figures came in at $68000.0 (Q4 2025), $178000.0 (Q1 2025), and $425000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Rockwell Medical | 29.77 Mn | 4.98 Mn | 3.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -450,000.00 |
| Jun 30, 2026 | -450,000.00 |
| Dec 31, 2025 | 68,000.00 |
| Dec 31, 2025 | 68,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Mar 31, 2025 | 178,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Sep 30, 2023 | 1.10 Mn |
| Dec 31, 2022 | 303,000.00 |
| Dec 31, 2022 | 303,000.00 |
| Sep 30, 2022 | 297,000.00 |
| Sep 30, 2022 | 297,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 10,000.00 |
| Dec 31, 2021 | 57,000.00 |
| Dec 31, 2021 | 57,000.00 |
| Jun 30, 2021 | 18,000.00 |
| Jun 30, 2021 | 18,000.00 |